Alexion to acquire Enobia for up to $1Bn in rare disease tie up
This article was originally published in Scrip
Executive Summary
Alexion Pharmaceuticals is acquiring privately held Enobia Pharma for up to $1.08 billion, consisting of $610 million in cash and potentially a further $470 million if various regulatory and sales milestones are achieved.